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ZACHARY T. BLOOMGARDEN, MD
T
his is the third of a series of articles
based on presentations at the Amer-
ican Diabetes Association Scientiﬁc
Sessions held 5–9 June 2009 in New Or-
leans, Louisiana, pertaining to incretin
physiology and incretin-based treatment
approaches.
Central nervous system effects of
glucagon-like peptide 1
At a symposium on nonislet effects of
glucagon-like peptide 1 (GLP-1) at the
American Diabetes Association (ADA)
Scientiﬁc Sessions, Remy Burcelin (Tou-
louse, France) reviewed the controversy
as to the extent of GLP-1 action mediated
in the central nervous system versus pe-
ripheral effects, advancing the concept
that a central effect of GLP-1 may be to
induce insulin secretion, but showing
studies suggesting that central adminis-
tration of GLP-1 decreases muscle glyco-
gen—an effect blocked with a GLP-1
receptor antagonist (1). If the central ef-
fect of GLP-1 is to increase insulin secre-
tion and to reduce peripheral glucose
utilization, it would be expected to in-
crease hepatic glycogen stores, which
could be useful in preparation for situa-
tions of decreased nutrient availability.
The nature of the signal sent to muscle
may be understood by recognizing that
muscleglucoseutilizationiscontrolledby
muscle blood ﬂow (2). In his group’s
studyofmusclebloodﬂow,centralGLP-1
administration blocked the increase in
muscle blood ﬂow seen with insulin and
glucose. Mice not expressing the GLP-1
receptor do not show this inhibition of
vasodilation and therefore have greater
insulin sensitivity with administration of
GLP-1. Addressing central GLP-1 signal-
ing mechanisms, Burcelin noted that hy-
pothalamic protein kinase C (PKC) is
increased with central GLP-1, whereas
the central administration of the PKC in-
hibitor calphostin C prevented the inhib-
itory effect of GLP-1 on muscle glucose
uptake. In contrast, activation of brain
PKC by phorbol-12-myristate, 13-acetate
infusion induced insulin resistance and
inhibitedvasodilation.Althoughthereare
more than 12 PKCs, anti-PKC ε appears
to block this GLP-1 effect. High-fat diet–
induced diabetes is associated with insu-
lin resistance (not seen in mice not
expressing the GLP-1 receptor) and in-
creased GLP-1–dependent brain PKC
activity, with PKC inhibition reversing
the insulin resistance and restoring the
vasodilatory action of insulin plus glu-
cose. Burcelin hypothesized that the
central effect of GLP-1 activates the
sympatheticnervoussystemcausingva-
soconstriction, while the peripheral ef-
fect of GLP-1 has the opposing action of
causing vasodilation.
Cardiac effects of GLP-1
Richard Shannon (Philadelphia, PA) dis-
cussed cardiac effects of GLP-1. The term
“preconditioning” refers to interventions
mitigating myocardial infarction size
when carried out in advance of the insult.
Suchmeasuresmaybeearlyorlatephase.
“Postconditioning” refers to the restitu-
tion of contractile dysfunction following
an insult. Contractile abnormalities after
ischemia involve myocardial hibernation,
whereas myocardial stunning involves
acuteﬂow-functionmismatchfollowinga
brief period of complete ischemia.
Early preconditioning involves up-
regulationoftheprotein-serine-threonine
kinaseandkeyintracellularregulatorAkt,
altering mitochondrial transport perhaps
involving a KATP channel, with pharma-
cological mediators including adenosine
and bradykinin. Mitochondrial ischemia
leads to apoptosis and necrosis. Ischemic
preconditioning activates Akt, increasing
intracellular calcium concentrations and
decreasing the mitochondrial electro-
chemical gradient. Late-phase precon-
ditioning is different; it involves
transcriptionfactoractivationleadingtoa
newclassofmediators.Coronarystenosis
decreasescontractilitywithP30mitogen–
activated protein kinase involved with
direct suppression of mitochondrial elec-
trochemical gradients.
The cardioprotective effects demon-
strated for GLP-1 have typically been
studied in the acute phase, with the agent
particularlypotentwhengivenpriortoan
acute insult. The process is cyclic AMP
dependent that involves phosphatidyl-
inositol 3-kinase (PI3K) and Akt, inhibit-
ing proapoptotic pathways. In chronic
heart failure models with rapid pacing, a
form of chronic stunning develops, asso-
ciated with insulin resistance and de-
creased myocardial glucose uptake. With
chronic GLP-1 infusion, myocardial glu-
cose uptake increases, without change in
insulin levels but with profound suppres-
sion of glucagon, and all cardiac function
parameters in such a model improve.
There are GLP-1 receptors in the myocar-
dium (3). GLP-1 receptor downregula-
tion occurs with infusion, however, and
Shannon noted that it is difﬁcult to show
aneffectofGLP-1oncardiacmyocytecal-
cium permeability, so that the exact me-
diators of GLP-1 cardiac effect are
uncertain. Furthermore, the cardiac
GLP-1 receptor may not respond to the
long-acting analogs developed for glyce-
mic treatment, and there is evidence that
some cardiac GLP-1 effects are mediated
by GLP-1 (9-36)—the product of action
of dipeptidyl peptidase (DPP)-4 on
GLP-1.
Metabolic effects of GLP-1 mediated
by direct action
Alan Cherrington (Nashville, TN) dis-
cussedinvitroactionsofGLP-1inmuscle
and liver and reviewed his studies show-
ing evidence of direct effects on these tis-
sues in his canine studies, further studies
ofdirecteffectsinman,andtheconceptof
portal vein glucose sensing.
In vitro studies show that GLP-1 in-
creases muscle glucose uptake and glyco-
gen formation (4), an effect inhibited by
the PI3K inhibitor wortmannin, suggest-
ing activation of intracellular glucose
metabolism pathways (5). Cherrington
commented that it is controversial
whether such direct metabolic effects of
GLP-1 occur, but given the number of
positive ﬁndings, he expressed his sense
that there is such a phenomenon. Similar
studies suggest hepatic effects of GLP-1
(6). The studies require, however, very
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be physiologically relevant, although im-
portant in demonstrating that there is a
receptor and a signaling mechanism.
Cherrington reviewed a number of
canine studies. In a study of depancre-
atized dogs given somatostatin to sup-
pressendogenousisletfunctionandgiven
infusions of insulin and glucagon, with
blood glucose clamped at 180 mg/dl,
GLP1 infusion did not change insulin or
glucagon levels; glucose levels were iden-
tical, and glucose production rates were
similar with and without GLP-1, but glu-
cose utilization was greater with the infu-
sion (7). Similar results have been
reported with infusion of exenatide, also
with evidence of direct hepatic effect (8).
Human studies have shown that GLP-1
decreased glucose production (9) and in-
creases glucose utilization (10). There is,
then, evidence that both muscle and he-
patic glucose uptake can be affected by
GLP-1 independent of its islet effects, but
Cherrington pointed out that it is not
known whether these effects are centrally
mediated or direct. In his studies, net he-
patic glucose balance can be measured
withdirectbloodﬂowandportal,arterial,
andhepaticveincannulation.Comparing
effects of peripheral, portal, and hepatic
artery GLP-1 infusion in dogs receiving
somatostatin plus glucose plus insulin
plus glucagon, arterial GLP-1 concentra-
tions were 50 pmol/l in all studies,
while with portal and hepatic infusions
hepatic levels were 100 pmol/l, putting
the range around that seen with oral glu-
cose ingestion. With portal infusions,
portal vein GLP-1 levels were higher
(hence activating portal vein sensors, if
such were to be present) (11). Glucose
levels increased to 225 mg/dl in all stud-
ies. Hepatic glucose uptake did not
increase with peripheral GLP-1 adminis-
tration but increased with either portal or
hepatic artery administration, suggesting
either a direct hepatic effect or hepatic
GLP-1 receptors activating central signal-
ing causing increased glucose uptake. Al-
though Cherrington thought that it is
unlikely that this would play a physiolog-
ical role, he pointed out that it may be
relevant to the effect of GLP-1 analog–
based treatment. When portal GLP-1 ad-
ministration was compared with hepatic
arterial GLP-1 administration, there was
no change in either insulin or glucagon
levels, but the glucose infusion require-
ment was greatest with portal GLP-1 and
intermediate with hepatic artery GLP-1
compared with levels seen in control an-
imals (12). Thus, Cherrington suggested,
GLP-1 does increase glucose uptake, and
portal glucose administration appears to
be required for the effect of GLP-1 on
muscle glucose utilization.
Possible role of GLP-1 (9-36)
Michael Brownlee (New York, NY) dis-
cussed evidence suggesting a role of
GLP-1 (9-36) in diabetic complications.
Hyperglycemia-induced mitochondrial
overproduction of reactive oxygen spe-
cies (ROS) activates four major pathways
of diabetic cellular damage. Intracellular
hyperglycemia increases mitochondrial
ROS causing DNA strand breaks in the
nucleus activating poly(ADP-ribose)
polymerase, which leads to the increases
in glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), leading to accumula-
tion of glycolytic metabolites, resulting in
increased polyol pathway ﬂux and in-
creased methylglyoxal, which in turn in-
creases advanced glycation end product
levels as well as increases expression of its
receptor RAGE, a toll-like receptor.
GAPDH also activates PKC that leads to
proinﬂammatorypathwayactivation,and
GADPHincreasespolyolpathwayactivity
(13).Hyperglycemiaalsoinhibitsthecrit-
ical antiatherogenic enzymes endothelial
nitric oxide synthase (eNOS) and prosta-
cyclin synthase, potentially exacerbating
atherosclerosis (14,15). In insulin-
resistant models, fatty acids also increase
ROS, activating and inactivating the same
pathways (16).
Although it has been thought that the
product of DPP-4 action on GLP-1,
GLP-1 (9-36), is inactive (17), Brownlee
reasoned that a potential role of GLP-1
(9-36) would be to inactivate the various
processes leading to ROS after nutrient
ingestion. He showed evidence that
GLP-1 (9-36) amide prevents ROS in-
duced by high glucose or fatty acids in
insulin-resistant states. In human aortic
endothelial cells, prostacyclin synthase
and eNOS are inhibited both by high glu-
coseandbyoleicacid,withpreventionby
GLP-1 (9-36). Normal humans lose pros-
tacyclin synthase activity after 3ho f
glucose infusion to levels of 10 mmol/l,
lasting for the subsequent 24 h. Diabetic
mice not expressing the GLP-1 receptor,
furthermore, show inhibition both of
eNOS and of prostacyclin synthase activ-
ity, which can be reversed by administra-
tion of GLP-1 (9-36).
Incretin-based treatment approaches
Clinical and basic science information
was presented for a number of agents act-
ing on the incretin system at the ADA Sci-
entiﬁc Sessions. Jessen et al. (abstract
1527) administered GLP-1 with a DPP-4
inhibitor and showed a lesser duration of
suppression of food intake than that seen
with exenatide, suggesting that exenatide
may have effects differing from those of
GLP-1 beyond its lack of susceptibility to
degradation by DPP-4. The GLP-1 recep-
tor antagonist exendin (9-39) was re-
ported by Stanley et al. (abstract 2) to
reduce hyperinsulinemia and prevent hy-
poglycemia associated with mutations in
the KATP channel, suggesting that GLP-1
receptor activation may play a role in the
pathogenesis of hyperinsulinism and that
antagonism of the receptor may have
therapeutic beneﬁts. Exenatide was the
subject of ongoing studies with reports of
an inhaled form and two different weekly
forms of the agent. Liraglutide, a daily
GLP-1mimetic,wasthesubjectofanum-
ber of reports. Albiglutide, a large recom-
binant protein with both albumin and
GLP-1 moieties (18), with sustained bio-
logical action over a period of 1 week
(19);taspoglutide;LY2189265,aDPP-4–
protected GLP-1 analog covalently linked
to an Fc fragment of human IgG4; and
NN9535 (about which no data were pre-
sented at the meeting) are other GLP-1
receptor agonists being studied with evi-
dence of efﬁcacy at weekly (or longer)
dosing intervals.
Exenatide immediate release
Shenetal.(abstract366)analyzedcardio-
vascular safety among 2,279 subjects re-
ceiving exenatide versus 1,629 control
subjectsandfound20and39%reduction
in cardiovascular end points with various
methodologies;althoughthemeanreduc-
tion in events was not signiﬁcant for ei-
ther agent, the 95% conﬁdence limits did
not include an increase in events by
30%, suggesting that these agents are
likely to be safe in terms of cardiovascular
events. Bruce et al. (abstract 578) studied
the same population, ﬁnding that tran-
sient, mild-to-moderate nausea occurred
in 39% of subjects receiving exenatide
compared with 9% of control subjects,
vomiting in 13% compared with 3%, and
pancreatitis in 0.3% compared with
0.3%, suggesting adequate gastrointesti-
nal tolerability of the agent. Horton et al.
(abstract 611) analyzed an electronic
medical record database that contains in-
formation on 6,280, 5,861, and 32,398
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and insulin, with weight losses of 3 and
1.1 kg and gain of 0.6 kg, respectively.
Weight loss in the former two groups was
associated with reduction in blood pres-
sureandtriglyceridelevels;thosepatients
receivingexenatidewithweightloss4.5
kg had reduction in LDL cholesterol as
well.
Arnolds et al. (abstract 526) treated
48 type 2 diabetic subjects with met-
formin and insulin glargine titrated over
4–8 weeks to a fasting glucose 100
mg/dl (75% reached this goal). Subse-
quently, exenatide, sitagliptin, or neither
wasaddedfor4weeks,withbothincretin
treatments associated with 16% reduc-
tion in 6-h postprandial glucose excur-
sion; in fasting glucose, to 82 and 84 vs.
89 mg/dl; and in A1C, to 6.5 and 6.4 vs.
6.7%.Weightdecreased0.9kg,increased
0.1 kg, and increased 0.4 kg with the re-
spective treatments, suggesting that addi-
tion of either a GLP-1 mimetic or a DPP-4
inhibitor may similarly beneﬁt insulin-
treated type 2 diabetic patients. Jogi et al.
(abstract615)treated8subjectsreceiving
metformin with pioglitazone 45 mg daily
and 10 such subjects with both pioglita-
zone and exenatide for 6 months. Piogli-
tazone alone decreased A1C from 7.9 to
7.2% and increased adiponectin 68%,
whilecombinedtreatmentdecreasedA1C
from 7.5 to 6.5% and increased adipo-
nectin 181%, although not signiﬁcantly
reducing weight. Christoﬁdes et al. (ab-
stract 572) treated 132 subjects with ex-
enatide and various combinations of
metformin and pioglitazone, while dis-
continuing sulfonylureas, with baseline
A1C 7.1%, and found that at 21 months
among47subjectsremainingforobserva-
tion, A1C was 6.3%, with 1.7 kg weight
loss.Theyalsotreated109type2diabetic
subjects receiving insulin, with baseline
A1C 8.1%, with exenatide; 43 were fol-
lowed through 21 months and had mean
A1C 7.3% and 4.3 kg weight loss. Sa-
marasinghe et al. (abstract 530) reported
on 22 insulin-receiving type 2 diabetic
patients treated with exenatide for at least
3 months and found 0.2% reduction in
A1C and in weight by 2.2 kg at 3 months;
mostpatientseitherreducedordiscontin-
ued insulin treatment. Hamdy et al. (ab-
stract 539), however, reported on 133
subjects treated with exenatide and ob-
served for at least 2 years and found that
84 continued the agent throughout the
period of observation, with 7.9-pound
weightloss,butwithA1Cincreasingfrom
7.9to8.0%overanaverageof30months.
Forty-nine patients stopped exenatide af-
ter a mean of 17 months, with 3.7-pound
weight loss, and again without signiﬁcant
change in A1C, suggesting dissociation in
durability between weight reduction and
metabolic improvement.
Baughman et al. (abstract 160) and
Costello et al. (abstract 446) compared
exenatide with inhaled GLP-1 adsorbed
onto Technosphere microparticles in
acute studies, ﬁnding reduction in gastric
emptying to be the principal mechanism
of the effect of the injected preparation,
whereas inhaled GLP-1 had a consider-
ably greater insulin-stimulatory effect,
with less effect on gastric emptying and
causing nausea in just 1 of 20 subjects
receivingtheagent.Theglucose-lowering
effect of the agent was greater in those
subjects with higher baseline glucose
levels.
Exenatide once weekly
Kim et al. (abstract 159) followed 181
subjects who received either exenatide
twice daily or the once-weekly exenatide
preparation for 30 weeks, followed (for
135 participants) by 70 weeks of the
weekly preparation, and reported that
A1C decreased from 8.3 to 6.5%, fasting
glucose from 167 to 130 mg/dl, and
weight from 100 to 96.4 kg. Nausea oc-
curred in 8% of subjects during the pe-
riod from 30 to 100 weeks. Bergenstal et
al. (abstract 6-LB) treated 160 type 2 dia-
betic subjects with exenatide weekly, 166
with sitagliptin 100 mg daily, and 165
with pioglitazone 45 mg daily. From
baseline A1C of 8.5%, levels decreased
1.6, 0.9, and 1.2% with the three agents;
fasting glucose decreased by 32, 16, and
27 mg/dl; and weight decreased by 2.7
and 0.9 kg versus increasing by 3.2 kg,
respectively. Wang et al. (abstract 553)
studied 224 type 2 diabetic subjects re-
ceiving a different extended-release form
of exenatide, conjugated to recombinant
human albumin, and found reductions in
A1C by 1.4, 0.8, 0.8, and 0.4% with 3.0,
2.0, and 1.5 mg and placebo doses, re-
spectively, with modest weight loss and
tolerable gastrointestinal side effects.
Liraglutide
Rosenstocketal.(abstract558)compared
the pharmacokinetics of exenatide with
thatofliraglutideandfoundtheformerto
show peak activity during the ﬁrst 4 h
after dosing, with reduction to baseline
after 8 h, whereas liraglutide led to rela-
tively consistent elevations in levels over
24 h. Finer et al. (abstract 1729) treated
176 obese pre-diabetic subjects with lira-
glutide1.2,1.8,2.4,and3.0mgdailyand
reported normal glucose tolerance in 69,
96, 88, and 96% after 20 weeks, whereas
only 41% of subjects treated with orlistat
120 mg thrice daily and 46% of control
subjectsshowednormalizationofglucose
tolerance. Seino et al. (abstract 536) ran-
domized 400 type 2 diabetic Japanese pa-
tientstoliraglutide0.9mgcomparedwith
glyburide 2.5 mg daily and found A1C
reduction of 1.7 vs. 1.2% at 24 weeks,
with hypoglycemia occurring 0.8 vs. 5.5
times per person per year and diarrhea in
6.3 vs. 3.8% of the two groups. Garber et
al. (abstract 162) compared liraglutide
with glimepiride for a 2nd year in 321 of
440 subjects completing a 1-year study,
ﬁnding A1C reduction from 8.1 to 6.9%
with 1.8 mg and from 8.0 to 7.1% with
1.2 mg liraglutide daily doses, while de-
creasing from 8.0 to 7.5% with
glimepiride;weightdecreased2.7and2.1
kg, while increasing 1.1 kg; and hypogly-
cemiaoccurred0.3,0.2,and1.8timesper
person per year with the respective treat-
ments. Nauck et al. (abstract 459) com-
pared 2,284 patients who received
liraglutide as substitute for an oral hypo-
glycemic agent with 1,683 patients who
received add-on of liraglutide to existing
treatment in six randomized phase 3 tri-
als.A1Cdecreasedfrom8.3to7.0%com-
pared with 8.4 to 7.4% with the 1.8-mg
dose and showed similarly greater reduc-
tion with the 1.2-mg dose, whereas re-
ductions in weight and in blood pressure
were similar with substitution and with
add-on. Fonseca et al. (abstract 545) per-
formed a meta-analysis of 1,363 and 896
subjects receiving liraglutide 1.8 and 1.2
mg daily compared with 524 receiving
placebo for 26 weeks and found a reduc-
tioninsystolicbloodpressureby2.5,2.6,
and 0.2 mmHg.
Other GLP-1 receptor agonists
Rosenstocketal.(abstract163),Reuschet
al. (abstract 461), and Stewart et al. (ab-
stract598)treated356type2diabeticpa-
tients with varying doses of albiglutide
and with exenatide twice daily for 16
weeks and reported A1C reductions from
baseline of 8% by 0.9% with albiglutide
30 mg weekly, by 0.8% with 50 mg every
other week, and by 0.9% with 100 mg
monthly,whereasreductionsof0.5%and
0.2%, respectively, were seen with ex-
enatide and placebo (20). Fasting glucose
decreased 26, 24, and 22 mg/dl with the
three albiglutide doses, 14 mg/dl with ex-
enatide, and 2 mg/dl with placebo. The
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time with the biweekly and monthly reg-
imens, suggesting that weekly dosing
would be optimal. Nausea and/or vomit-
ing occurred in 46% of subjects receiving
exenatideandin29,54,and56%ofthose
receiving 30-, 50-, and 100-mg doses
weekly, biweekly, and monthly, respec-
tively. Seino et al. (abstract 581) adminis-
tered the agent to 40 Japanese type 2
diabetic subjects and reported a half-life
just over 5 days, also with highest side
effect frequency and lowest efﬁcacy with
the 100-mg monthly dose (21).
Umpierrez et al. (abstract 12-LB)
treated 262 obese type 2 diabetic subjects
with LY2189265 for 16 weeks, reporting
a reduction in A1C from basal level aver-
aging 8.2% by 0.3% with placebo, 1.3%
both with 0.5 and with 1.0 mg weekly,
and 1.5% with 2.0 mg weekly. Fasting
glucosedecreasedby9,38,and48mg/dl,
respectively, and weight loss of 1.6, 1.4,
and2.5kgwasrecordedat0.5-,1.0-,and
2.0-mgweeklydoses.Nauseaoccurredin
13%, diarrhea in 9%, and abdominal dis-
tension in 8% of treated patients. Bar-
rington et al. (abstract 161) reported a
5-week study with this agent of 43 type 2
diabetic patients and found A1C reduc-
tions of 0.7 to 1.3% with 0.05- to 8-mg
weekly doses.
Sewing et al. (abstract 323) and Se-
bokovaetal.(abstract593)studiedtaspo-
glutide in the Zucker diabetic fatty rat
model, reporting weight loss, improved
glycemia, and 30% reduction in glu-
cose-dependent insulinotropic peptide
(GIP) and 70% reduction in peptide-YY
(PYY) levels after glucose challenge with-
out change in fasting levels, the latter per-
haps reﬂecting suppression of L-cell
activity by GLP-1 receptor activation.
Treatment also improved homeostasis
model assessment-insulin sensitivity and
1,5-anhydroglucitol, a measure of post-
prandial glycemia. A human study has
been reported with this agent (22).
Oral agents acting via the incretin
system
A novel set of G-coupled protein recep-
tors (GPRs) involved in incretin systems
appears to be activated physiologically by
speciﬁc long-chain fatty acids and their
derivatives, playing roles in the effects of
fats on islet (and incretin) function and
potentiallyofferingapathwayindevelop-
ment of new therapeutic agents (23).
Lauffer et al. (abstract 151) studied the
L-cell receptors GPR40, GPR120, and
GPR119 and reported stimulation of
these receptors to acutely increase GLP-1
secretion, as well as to enhance glucose-
induced insulin secretion. Chronically,
GPR119 agonists reduced but a GPR 40/
120 agonist increased L-cell apoptosis.
One GPR 119 agonist, but not another,
and an agonist of both GPR 40 and
GPR120 reduced L-cell proliferation, sug-
gesting that GPR119 agonists might have
promiseinofferingcombinedstimulation
ofbothGLP-1andinsulinsecretion.Rob-
erts et al. (abstract 164) administered an
orally available GPR119 agonist, MBX-
2982, in rodent diabetes models and
found a decrease in blood glucose after
oral glucose with increase in active GLP-1
levels, reduction in gastric emptying, and
delay in the time to onset of diabetes in a
high-fat diet–fed model, with effects in-
creasedbytheDPP-4inhibitorsitagliptin.
In subjects with elevated fasting glucose,
MBX-2982loweredbloodglucoseandin-
creased the insulin secretory response to
glucose.Tanakaetal.(abstract464)stud-
iedanotherGPR119agonist,AS1907417,
similarly showing glucose lowering in di-
abetesrodentmodelswithpreservationof
-cellfunction.Swainetal.(abstract453)
administered an agent acting both to in-
hibit DPP-4 and to activate GPR119,
showing greater glucose-lowering effect
inarodentmodelthanthatseenwithsita-
gliptin. In another study of overlap be-
tween a -cell stimulatory agent and the
L-cell, Kitahara et al. (abstract 1427) re-
ported that nateglinide increased portal
blood GLP-1 levels in a rodent model and
that in vivo incubation of human intesti-
nal L-cells with nateglinide stimulated
GLP-1 release in a dose-dependent fash-
ion,associatedwithincreaseinintracellular
calcium, but unaffected by potassium-ATP
channelopeningagentsorbysulfonylureas,
suggesting that the agent has a more direct
effect in increasing L-cell intracellular cal-
cium levels.
Transcription factor 7-like 2 (TCF7L2)
gene variants are strongly associated with
type 2 diabetes. Maedler et al. (abstract
1160) reported that decreased TCF7L2
protein is seen with these variants in as-
sociation with reduced expression of islet
GLP-1 and GIP receptors and with re-
duced glucose-stimulation of insulin se-
cretionbyGLP-1andGIP.Itisinteresting
to speculate that the presence of the at-
risk polymorphisms might be a marker
for differences in response to incretin-
based treatments. Kawamori et al. (ab-
stract90-LB)administeredGLP-1tomice
lacking -cell insulin receptors and to
controls and found that the knockout
mice increased acute GLP-1–mediated
glucose lowering and improved glucose
tolerance and insulin secretory response
to oral glucose, with evidence of -cell
proliferation. The -cell insulin receptor
may then mediate direct short-loop feed-
back inhibition by insulin, with -cell in-
sulin resistance then paradoxically
enhancing insulin secretion.
The DPP-4 inhibitors, increasing cir-
culatinglevelsofGLP-1andGIP,areclin-
ically available and were the subjects of a
number of reports at the meeting, includ-
ing meta-analyses of multiple studies of
speciﬁc agents and long-term extension
studies of earlier phase 3 clinical trials.
Wolf et al. (abstract 8-LB) studied overall
acute coronary end points, major acute
coronaryendpoints,andtotalandcardio-
vascular mortality and found that in com-
parison with 3,356 type 2 diabetic
subjects receiving saxagliptin, rates of the
various events increased 63%, doubled,
tripled, and quadrupled, respectively, in
1,251 control subjects not receiving the
agent, suggesting cardiovascular safety.
DeFronzoetal.(abstract547)presenteda
2-year follow-up of 743 metformin-
treated type 2 diabetic subjects (with ini-
tial A1C of 8.0%) randomized to addition
of saxagliptin versus placebo; placebo-
adjusted reductions in A1C of 0.6, 0.7,
and 0.5% were seen in 181, 184, and 177
subjectsrandomizedtosaxagliptin2.5,5,
and 10 mg daily, respectively. Although
58, 52, and 57% of these groups discon-
tinued (or were given rescue treatment
with pioglitazone) for lack of glycemic
control, 72% of those in the placebo
group discontinued or required rescue
treatment. Pratley et al. (abstract 462)
compared the effect of alogliptin in 1,611
type 2 diabetic subjects aged 65 years
and in 455 subjects aged 65 years,
showingplacebo-adjustedA1Creduction
by 0.5–0.6% from baseline levels of
8–8.4% that were similar in younger and
older subjects, although with adverse
events leading to discontinuation re-
ported in 2% of younger but in 4% of
older patients. Linagliptin, placebo, or
glimepiridewasadministeredto333met-
formin-treated type 2 diabetic subjects
with baseline A1C 8.3%; 0.7–0.8% pla-
cebo-corrected A1C reduction was found
with linagliptin (5 mg and 10 mg), but
0.9%reductioninA1Cwasreportedwith
glimepiride at 12 weeks. Hypoglycemia
occurred in no patients receiving placebo
or linagliptin and in three patients receiv-
ingglimepiride.Linkeetal.(abstract596)
reported improvement in an experimen-
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rodent model with linagliptin treatment,
which might reﬂect the improvement in
glycemia with the agent or a nonglycemic
beneﬁt, and Jin et al. (abstract 833) re-
ported reduction in peripheral nerve de-
generation in a diabetes-related rodent
model treated with vildagliptin—another
beneﬁt that might be attributed to either
glycemic change or non–glucose-mediated
effect.
Vilsboll et al. (abstract 588) random-
ized641type2diabeticpatientsreceiving
insulin alone or with metformin to addi-
tionofsitagliptincomparedwithplacebo.
A1C decreased from 8.7% by 0.6% with
sitagliptin versus not changing with pla-
cebo, although 16% compared with 8%
had hypoglycemic events. Williams-
Herman et al. (abstract 540) reported a
2-year follow-up of sitagliptin mono-
therapyin147subjects,withreductionin
mean A1C from a baseline of 8.5% to
6.9% in the 32 patients remaining in the
study, and of sitagliptin addition to met-
forminin852patients,withA1Cdecreas-
ingfromabaselineof8.0%to6.9%inthe
347 patients remaining. The substantial
decrease in numbers of participants
makes it difﬁcult to evaluate the durabil-
ity of beneﬁt of the agent. Yoon et al. (ab-
stract 522) treated 520 treatment-naïve
type 2 diabetic patients who had baseline
A1C of 9.5% with sitagliptin 100 mg plus
pioglitazone 30 mg daily or with pioglita-
zone alone for 24 weeks and found A1C
reduction of 2.4 vs. 1.5%, with greater
improvementininsulinandC-peptidere-
sponses to a meal challenge in the former
group. Approximately 1% of patients in
both groups had hypoglycemia, 6 vs. 7%
had gastrointestinal adverse events, and 3
vs. 4% had edema. Aaboe et al. (abstracts
605 and 606) randomized 22 metformin-
treatedtype2diabeticsubjectstositaglip-
tin compared with placebo for 12 weeks;
the former group exhibited improved in-
sulin secretory responses to glucose and
arginine, demonstrable after the 1st week
of treatment. PYY (total) levels decreased
26%, with PYY (3-36) levels reduced
63%,whereasPYY(1-36)levelsincreased
24%, reﬂecting the action of DPP-4 on
PYY and, perhaps, short-loop negative
feedback of PYY (1-36). The researchers
speculate that the lack of weight loss seen
clinically with DPP-4 inhibitors may be
duetoreductionincirculatingPYY(3-36)
levels with the agents, based on under-
standingofthephysiologicaleffectsofthe
two PYY species (24).
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